The investigators first generated disease-specific proteomic scores using measurements from 999 plasma proteins in 50,673 UK Biobank participants. That was the discovery step. They then validated these proteomic signatures in 9,358 participants from the Prospective Urban and Rural Epidemiological (PURE) study. Next, in PURE, the study team integrated the validated proteomic scores with 2,279 polygenic scores and 479 DNA methylation scores to assemble four composite multiomic risk tools, called MEGASCOREs, aimed at predicting myocardial infarction (MI), atrial fibrillation (AF), heart failure (HF), and cardiovascular mortality.
Cohort breadth was substantial. The analysis reported pooled results across PURE and two additional cohorts; the abstract did not name those additional cohorts. The source did not report assay platforms, specific feature-selection algorithms, or the exact weighting strategy used to combine protein, genetic, and methylation inputs in the abstract. Investigators reported external validation in PURE, and they evaluated discrimination, calibration, and ancestry-specific performance in the pooled datasets described in the manuscript abstract.
Across pooled analyses, each standard-deviation rise in the corresponding MEGASCORE associated with materially higher hazards for the target outcomes. The authors reported hazard ratios with 95% confidence intervals: MI (HR, 2.13; 95% CI, 1.86–2.43), AF (HR, 1.94; 95% CI, 1.68–2.24), HF (HR, 3.33; 95% CI, 2.75–4.05), and cardiovascular mortality (HR, 3.28; 95% CI, 2.33–4.61). Short sentence: effects were largest for HF and cardiovascular death.
Discrimination improved when MEGASCOREs were added to clinical prediction models. MEGASCORE-CV-Death achieved an area under the receiver operating characteristic curve (AUC) of 0.83 (95% CI, 0.82–0.85) for cardiovascular mortality versus 0.78 (95% CI, 0.77–0.80) for SCORE2, as reported by the authors. The study team observed higher discrimination with MEGASCORE-CV-Death than with SCORE2 across all four ancestry groups they analyzed. Calibration also favored MEGASCORE-CV-Death in non-European ancestry groups, per the abstract. The abstract did not list numeric calibration statistics by ancestry.
The authors reported that MEGASCOREs remained associated with cardiovascular outcomes among participants who lacked conventional cardiovascular risk factors. That finding suggests the multiomic signatures capture biological risk not fully reflected in standard clinical measures. Short, direct fact: associations persisted in low-risk subgroups. The source abstract did not provide details on which conventional risk factors were absent in these subgroups nor the subgroup sample sizes; those specifics are likely in the full manuscript.
This report is a preprint and has not undergone peer review. The abstract therefore presents headline results but omits several operational and translational details. The source did not report, in the abstract, the names of the two additional cohorts used in pooled analyses, assay platforms, model-building hyperparameters, or cost and feasibility data for clinical deployment. The abstract also did not provide prospective, randomized evidence that using MEGASCOREs to guide management improves patient outcomes.
Open questions remain. Which proteins and methylation loci carried the greatest predictive weight? How stable are these multiomic signatures over time and with intercurrent illness? What are the logistical and economic barriers to wide-scale implementation, especially in low-resource settings and across diverse ancestry groups? The authors documented improved discrimination and calibration versus SCORE2, but prospective clinical-validation steps and pathway-to-regulatory-approval milestones were not reported in the abstract.
Clinicians and researchers should treat these findings as hypothesis-generating until the full manuscript passes peer review and the detailed methods, cohort lists, and supplementary analyses are available. The data reported indicate that integrating proteomic, polygenic, and methylation information can add prognostic information beyond conventional clinical variables, with particularly large effect sizes for heart failure and cardiovascular mortality. Ending point: the preprint does not supply the implementation roadmap or prospective trial evidence needed to support routine clinical adoption.